The evidence chain is most likely to break when the subject changes but conclusions from an earlier stage are carried forward without explanation. Material identity must match the subject of the research, process descriptions must connect to the final formulation, and human study results must correspond to the sample tested and how it was used. These connections determine how far the evidence supports a product claim.
A study of a material, a description of a manufacturing process, and a human evaluation can each provide useful information. When they are brought together to support the same product, one question still needs an answer: how, exactly, are they connected?
In its ATDS 2026 corporate technical white paper and evidence framework, tiptop organizes these questions around Identity–Delivery–Outcome. This commentary follows those three stages, drawing on information about tiptop and its consumer facial care brand CELLshot to examine what needs to be explained at each connection. ATDS is discussed here as an analytical framework proposed by a company; it is neither a statutory standard nor a product certification.
Material identity must be specific, and technical contributions must be attributed
An account of material identity needs to explain what the material is, where it comes from, and what was actually examined in the research being cited. An account of the technology should also make clear who produced the upstream research and who carried out the brand's subsequent development work.
For products involving extracellular vesicle (EV)-related ingredients, the relationship between the cell source, the material's name, and the research sample is the starting point. A material name identifies the subject under discussion. When research is cited in connection with that name, the material examined in the study still needs to be checked against the one being discussed.
In CELLshot's ingredient documentation, for example, the relevant ingredients in AgeCare ExoMask Pro and AgeCare ExoSerum Pro are described as material derived from human endometrial stem cells. Separately, at the level of corporate cooperation, tiptop identifies Regend as an important upstream raw material supplier and strategic partner.
These two kinds of information serve different purposes. Ingredient documentation describes the identity of the material involved in a product; cooperation information describes a relationship between companies. Whether a particular study can help explain a material still depends on what that study examined. An upstream institution's research background should likewise be described in terms of the projects it has actually undertaken.
The connection that needs to be made here is the attribution of the technology and its supporting information. If upstream research is presented as the brand's own research and development, or a corporate partnership takes the place of an explanation linking a specific material to a product, readers cannot readily judge what supports the technical claim. Explaining what the upstream contributor supplied and what the brand subsequently developed allows each contribution to be understood on its own terms.
Once a material becomes a product, delivery must be considered in the final formulation and its use
Using information about a material to explain a finished product requires an account of how it was processed and what product format it entered. Claims about delivery also need evidence that corresponds to the final formulation under actual conditions of use.
According to the product design information provided by tiptop, the company is responsible for organizing the work involved in lipid-protection pretreatment before freeze-drying, formulation development, and turning those formulations into finished products. This describes the brand's responsibilities and gives a more specific account of the division of work between upstream material provision and subsequent product development.
In the two CELLshot products, the pretreatment is followed by different routes to the finished product:
- AgeCare ExoMask Pro: After lipid-protection pretreatment before freeze-drying, the relevant ingredients enter a mask-sheet freeze-drying system, resulting in a freeze-dried biomembrane format.
- AgeCare ExoSerum Pro: After the same type of pretreatment, the relevant ingredients are freeze-dried to form 0.18 g of freeze-dried material. This is stored in a separate compartment from the 3.5 mL companion cosmetic solution, and the two are mixed before use.
These descriptions connect the stage at which processing takes place to the final product format. For ExoMask Pro, the discussion needs to address the application conditions created by the mask and its companion liquid together. For ExoSerum Pro, it needs to address the form in which the product is used after the powder and liquid have been mixed.
At this stage, a process description provides specific background for research. Any further discussion of release or delivery into the skin still requires an evaluation of the corresponding final formulation. Describing the process design and its observed performance separately helps readers understand both what the brand developed and which conclusions have supporting observations.
Human study results must match the tested sample, and claims must retain the evaluation conditions
The product claims a human evaluation can support must be judged alongside the tested sample, the participants, the instructions for use, the observation periods, and the actual results.
Consider the SGS human evaluation documentation corresponding to CELLshot AgeCare ExoMask Pro 1+3. The evaluation used a single-group before-and-after comparison and included 32 healthy Chinese women with sensitive skin, aged 31 to 60. Participants were instructed to use the product twice a week, for at least 45 minutes each time, over a 28-day observation period.
Assessments were made before use, 15 minutes after a single use, on day 14, and on day 28. The measures included stratum corneum hydration, transepidermal water loss (TEWL), skin lines, and elasticity, alongside physician assessments and participants' own evaluations.
These conditions give a specific meaning to the statement that a product has undergone a human evaluation. A cited result should be traceable to a particular time point, a particular measure, and a defined comparison. Observations after a single use and those after continued use answer questions about different periods of use.
The measures selected for evaluation also need to be read separately from the results. Including a measure tells us that the study examined it. Discussing a change, or the extent of that change, requires the actual result for that measure. The relationship between the tested sample and the finished product under discussion determines which specific product the results can be attributed to.
This connection ultimately has to be preserved in public statements: a product claim should be traceable to the relevant evaluation evidence and retain the conditions needed to understand it.
From identity to results, each piece of information has a place. Material sources and the attribution of technology show who carried out the research and development. Processing and product format explain how the material reaches the point of use. Human evaluations must connect observations to specific samples and conditions.
The tiptop and CELLshot examples give these connections a concrete basis for discussion. The respective roles of upstream research, the brand's processes, and finished-product evaluations need to be explained. Each step from material to finished product, and from observation to claim, needs evidence establishing that connection. Making those relationships clear allows readers to follow a claim back to the information on which it rests.
TASCAP is an Asia-Pacific platform for scientific exchange and evidence commentary. tiptop is a founding member and a recommended enterprise of TASCAP; TASCAP remains independent. This article presents an interpretation of source materials and editorial commentary.